<DOC>
	<DOCNO>NCT01933958</DOCNO>
	<brief_summary>The objective study assess safety effectiveness Regorafenib use real clinical practice</brief_summary>
	<brief_title>Regorafenib Post-marketing Surveillance Japan</brief_title>
	<detailed_description>This study regulatory post-marketing surveillance Japan , local prospective observational study patient receive Regorafenib gastrointestinal stromal tumor progress cancer chemotherapy . A total 135 patient enrol assessed 6 month standard observational period . At 12 month 24 month first administration Regorafenib confirmation efficacy information include treatment duration survival status patient .</detailed_description>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<criteria>Patients treat Regorafenib/ STIVARGA meet product label . Patients treat Regorafenib/ STIVARGA n't meet product label .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Regorafenib</keyword>
	<keyword>Gastrointestinal stromal tumor</keyword>
</DOC>